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An effective antibody-based HIV-1 vaccine would ideally elicit potent antibodies 
capable of neutralising a wide range of HIV-1 isolates to better cover the human 
population. A primary concern is the virus’ ability to rapidly escape an antibody 
response. A strong neutralising response elicited by a vaccine may, in principle, select 
for viruses that are highly antibody resistant thereby significantly reducing the benefit 
of a vaccine. It is therefore important to study and better understand highly 
neutralisation resistant viruses. To this effect, we characterized sets of subtype C and 
CRF02_AG viruses whose neutralisation phenotype were well defined using within 
subtype neutralisation (neutralisation by subtype matched sera). Our main aim was to 
determine if there exists a relationship between neutralisation resistance and entry 
efficiency. Very highly neutralisation resistant viruses appear under-represented in the 
population. We hypothesised that this may be at least partially explained by decreased 
entry efficiency as changes to Envelope (Env) during escape could affect the entry 
process and provide opposing selective pressure that discourages the appearance of 
very highly neutralisation-resistant viruses.  
 
By comparing entry efficiencies of tier 3 viruses (highly resistant) to tier 2 
(moderately resistant) and 1B (sensitive), we observed that the tier 3 viruses generally 
exhibited higher entry efficiency. This was the opposed of what we hypothesised at 
the outset of these experiments. We also measured characteristics of resistant HIV-1 
Envs that can be inferred from the primary sequence such as the variable loop lengths, 
number of glycans and net charge.  We found that the V2 net charge and the V5 loop 
length were associated with neutralisation resistance in subtype C viruses and the V2 
loop length was associated with resistance in the CRF02_AG viruses. By analysing 
glycosylation patterns between the groups, we found that the presence of an N-linked 
glycan at position 413 and the lack of a glycan at N332 were predictors of 
neutralisation resistance in subtype C viruses. Tier 3 viruses were also more resistant 
than tier 2 and 1B viruses to the PGT121 (V3/glycan), 4E10 (MPER) and the CD4 
binding site broadly neutralising antibodies VRC01 and 3BNC117; suggesting that 
the epitopes of these antibodies are important for driving resistance. Furthermore, we 
found no significant relationship between susceptibility to the entry inhibitors 
Maraviroc and PSC RANTES (CCR5 antagonists) and the fusion inhibitor T20 and 
resistance, indicating that neutralisation resistance did not alter inhibitor target sites.  
 
Based on our findings, it is clear that reduced entry efficiency does not explain why 
highly resistant viruses are not more common. We may speculate that the 
evolutionary steps needed to reach very high neutralisation resistance may be difficult 
to go through and/or that other countervailing selective pressures may be involved. In 
the context of an antibody based intervention, highly resistant viruses with increased 
entry efficiency circulating in the population could be a set back in the control of the 
HIV-1 epidemic. Therefore, for any long-term antibody-based intervention to be 
globally relevant it must elicit responses that limit occurrence of resistance and also 
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Human immunodeficiency virus-1 (HIV-1), the causative agent of Acquired 
Immunodeficiency Syndrome (AIDS), has claimed an estimated 35 million lives since its 
identification in 19811. As of 2016, there were 36.7 million people living with HIV-1 
worldwide. Majority of them in sub-Saharan Africa. South Africa alone contributes 19% of 
the global number of people living with HIV-1, 15% of new infections and 11% of AIDS 
related deaths1.  
A vaccine would be crucial in the fight against the HIV-1 virus2. Most of the licensed 
vaccines targeting other viruses function mainly by eliciting the production of protective 
antibodies3. In HIV-1 infection, the role of neutralising antibodies (nAbs) has been 
extensively studied2. Passive immunisation studies on non-human primates (NHPs) provide 
the most convincing evidence suggesting that such antibodies can prevent infection4–6. These 
studies demonstrated that passive immunisation with nAbs before HIV-1 challenge protected 
against acquisition of infection in NHPs and support the development of an antibody based 
HIV-1 vaccine. The target of these nAbs is the HIV-1 surface glycoprotein, Envelope (Env)7; 
a protein required for viral entry into target cells8. Thus, antibody-based vaccine immunogen 
development has been focused on Env.  
One of the greatest challenges facing antibody-based vaccine development is the rapid escape 
of HIV-1 from the nAb response9. This escape could present a significant barrier to the 
efficacy of vaccine-induced nAbs in the population. Theoretically, escape from vaccine-
mediated antibody responses could select for neutralisation-resistant viruses that could 
circulate in a vaccinated population, thus substantially reducing any benefits of a vaccine. 
Furthermore, several studies have reported that viruses are evolving towards a more 
neutralisation-resistant phenotype as the epidemic progresses10–12. For these reasons, it is 
important to study and characterise highly neutralisation resistant HIV-1. A study of these 
viruses will likely illustrate some of the unique Env features associated with neutralisation 
resistance and have potential implications for immunogen design. This thesis will focus on 
characterising a panel of highly neutralisation resistant viruses and investigating the effect of 




1.2 Literature review 
1.2.1  The global epidemiology of HIV-1 
!
The HIV-1 epidemic is highly dynamic with different viral variants arising all over the 
world13. HIV-1 has been classified into four lineages; groups M, N, O and P, each of which is 
thought to have arisen from a separate transmission into the human population13–15. The vast 
majority of HIV-1 infections (and virtually all HIV-1 infections outside west and central 
Africa) belong to group M13,16. Within this group, nine subtypes are recognized; A, B, C, D, 
F, G, H, J and K along with recombinant forms13,17. Four subtypes (A, B, C and D) and two 
presumed circulating recombinant forms (CRF01-AE and CRF02_AG) account for most of 
HIV-1 infections (Fig 1.1)13.  Within the Env glycoprotein on the surface of the virus alone, 
amino acid sequences can differ up to 20% within a particular subtype and over 35% between 
subtypes18,19.   
 
      
 
 
Figure 1.1 Global distribution of HIV-1.  The distribution of HIV-1 group M subtypes and recombinant 
forms is indicated.  Africa shows the greatest diversity with subtype C dominating Southern Africa and 
CRF02_AG prevalent in Western Africa218.  
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1.2.2 Controlling the HIV-1 epidemic 
!
Certain measures have been introduced in a bid to control the HIV-1 epidemic. The wide 
introduction of highly active anti-retroviral therapy (ART) particularly in high prevalence 
countries such as South Africa, has contributed to a 48% decline in AIDS-related deaths 
between 2005 and 20161. Prevention strategies targeting transmission have also played a role 
in reducing HIV-1 incidence. Behavioural interventions aimed at preventing sexual 
transmission of HIV-1 include promotion of safe sex practices such as use of condoms, 
regular HIV-1 testing, promoting compliance to ART20 and understanding noncompliance21, 
male circumcision22 and having one sexual partner23. Other interventions include the roll out 
of pre-exposure (PreP)24 and post exposure prophylaxis (PEP)25 for at-risk individuals and 
ART for prevention of mother to child transmission (PMTCT)26.  
 
1.2.3 An HIV-1 vaccine: challenges and possible solutions 
!
While prevention strategies have played a key role27 in reducing the burden of HIV-1, the 
number of new infections remains high. In 2016 alone, there were an estimated 1.8 million 
new infections worldwide1. Prevention strategies that are ART based such as PreP and PEP 
rely on strict adherence to be successful28.  In particular, this requires continuous 
uninterrupted access to medication29,30 which is difficult to achieve in some settings. Adverse 
reaction to ART use is also of concern31,32. Putting these factors into consideration, other 
strategies are needed to fill the prevention gaps that remain.  
Vaccines have long been one of the most efficacious and cost effective methods of 
controlling and eradicating infectious diseases33. Consequently, one of the primary efforts of 
HIV-1 research remains the development of an effective vaccine. A recent study predicted an 
estimated 67% decline in HIV-1 incidence if a vaccine with even partial efficacy (30%) was 
introduced34. Considering the number of new infections in 2016 alone, this could have a 
substantial long term impact on the HIV-1 burden especially in Southern Africa, where HIV-
1 incidence remains particularly high. Several vaccine strategies have been explored35–37. The 
RV144 trial in Thailand remains the only vaccine study to show some promise with 31% 
efficacy (95% CI, 1.1 to 52.1; p=0.04)38. Although this vaccine showed only modest efficacy, 
it was proof that a vaccine against HIV-1 was plausible.   
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One major challenge impeding the development of an effective vaccine is the enormous 
diversity of HIV-1. Diversity is driven by several factors including high viral replication rates 
coupled with high mutation rate by the viral reverse transcriptase that lacks proof reading 
activity39. In addition, genetic recombination that occurs when an individual cell is infected 
by more than one strain13 generates new hybrid viral variants, some of which circulate 
widely. Selective pressure from the host also drives viral diversification40 because immune 
responses in an infected individual lead to selection of escape mutants. Goulder et al. (2001) 
showed that due to cytotoxic T cell pressure, viruses developed mutations in the cytotoxic T 
cell epitopes and that these mutants could be transmitted41. Selection pressure by nAbs has 
also been well documented42–44. Escape from nAbs results in the accumulation of escape 
mutations in circulating viruses. These factors contribute to the continuous evolution of HIV-
1 not only within the infected host but also within the population. Overcoming this diversity 
is crucial in developing a HIV-1 vaccine that is universally applicable. 
One approach that is being explored is the development of an effective sterilising vaccine that 
targets the transmitted virus before it establishes a persistent infection. This approach is 
supported by two important findings. First, reports state that up to 80% of productive HIV-1 
infections are a result of a single virus45–48. Secondly, as described above, outcomes from 
passive immunization studies in NHP show that presence of nAbs targeting the infecting 
virus before HIV-1 challenge protected the animals from infection4,6. Together, this means 
that even a vaccine with partial coverage can still be protective if it blocks the transmitted 
virus before the infection disseminates.  
 
1.2.4 Design of a HIV-1 vaccine immunogen based on Env 
!
The antibody-based HIV-1 vaccine candidates tested have targeted the surface envelope 
glycoprotein (Env). It is an attractive vaccine target as Env mediates viral entry49 into target 
cells and is the target of broadly neutralising antibodies (bnAbs)7. These antibodies are 
capable of neutralising diverse HIV-1 isolates from different subtypes50. Thus, the goal of a 
vaccine would ideally be to induce the production of bnAbs in sufficient quantities. With the 
exception of the RV144 trial mentioned above, trials using recombinant gp120, a subunit of 
Env, have all failed51. For this reason, strategies have switched to using better approximations 
of the Env trimer spike as an immunogen52. The rationale behind this is that an immunogen 
! !
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based on the trimer likely presents nAbs epitopes in a manner that best reflects the native Env 
spike. Although simpler forms of Env may present the same epitopes, they may not do so in a 
way that specifically mimics how they are presented on the native spike53,54. Most bnAbs 
recognize epitopes that are, to various extents, influenced by the quaternary structure of the 
trimer55–57. More specifically, the structure of the spike constrains how such epitopes are 
presented. While this strategy may not guarantee generation of bnAbs, it increases chances of 
inducing nAbs targeting conformational dependent epitopes. 
bnAbs are useful in guiding immunogen design as they elucidate potential vaccine targets. 
However, bnAbs exhibit unusual characteristics such as long hypervariable loops, self-
reactivity and extensive somatic hyper-mutation58 and this suggests that eliciting these types 
of responses will be challenging.  During antibody development in the course of an infection, 
the process of affinity maturation usually leads to accumulation of mutations (about 15%) on 
the variable antigen-binding region. However, bnAbs against HIV-1 gp120 exhibit a 
significantly increased number of mutations compared to the germline antibody (up to 46% in 
CD4 binding site antibodies)59,60. Deep sequencing and structural analysis suggested that 
there exists a number of affinity maturation intermediates in the bnAbs development 
pathway61. These intermediates of differing maturity may eventually evolve to give rise to 
bnAbs. This level of affinity maturation would have to be reproduced in the context of a 
vaccine and should be taken into consideration when designing an immunogen62.  
 
1.2.5 The structure and conformation of the HIV-1 Envelope 
!
Due to the important role Env plays, it has been widely accepted that a thorough 
understanding of the structure and conformations of Env is important for vaccine design63. 
The surface of a newly produced HIV-1 virion contains approximately 70 spikes that consist 
of trimers of a heterodimer of a gp41 trans-membrane subunit non-covalently bound to a 
gp120 subunit64. Before expression on the surface of an infected cell, the envelope proteins 
undergo processing and trimerisation. The envelope first exists as a gp160 protein precursor 
that is cleaved enzymatically into gp120 and gp41 subunits65. The mature, processed 
oligomer is then attached to the membrane by the C-terminal end of gp41 and most of the 
gp41 and gp120 molecule is expressed extracellularly. The gp120 subunit contains five 
! !
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variable regions (V1-V5) and five relatively conserved regions (C1-C5)66. The conserved 

















On the other hand, the variable regions, with the exception of the V5, contain disulphide 
bonds at their bases which form surface exposed loops67. The V1 and V2 loops contain great 
sequence and length variation amongst different isolates. The loop characteristics of the V1 
and V2 have been associated with sensitivity to neutralisation and disease progression68,69.  
The epitopes on the V1/V2 and V3 are often the most exposed and some serve as targets for 
neutralising antibodies70–73. Additionally, the V3 region plays a key role in co-receptor 
usage74. These variable loops are also important for protecting the conserved epitopes from 
antibodies75. Following variable loop removal, several of the conserved epitopes spanning the 
CD4 binding site were found to be more accessible to antibodies76.  The function of the V4 
and V5 loops is not well as known, although their deletion led to poor Env expression on the 
surface of the virus77.  
Figure 1.2 Model of the HIV-1 Env trimer. A ribbon representation of the Env trimer comprising gp120 
(red) and gp41 (blue) based on the crystal structure of BG505 SOSIP.664. The variable loops V1, V2, V3 and 
V4 are shown. Dotted loops indicate that the region was not fully resolved on the crystal structures7. 
! !
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The gp120 protein is highly glycosylated with up to 50% of its mass comprising glycans78. 
They are of host origin, added at different sites on the proteins (potential N-glycosylation 
sites; PNGs) and characterized by an N-X-T/S motif where X is any amino acid with the 
exception of proline79. These carbohydrates play numerous roles including correct folding of 
gp12080 and antibody evasion42 . The gp41 subunit is also glycosylated albeit at a much lower 
density. Interestingly, the isolation of bnAbs 2G12 and PGT121-13081 showed that 
neutralising antibodies can target glycans.  
Structural determinations on in vitro produced Env trimers have revealed that different 
conformational ‘faces’ of Env are exposed. Conformational changes are evident in the Env 
depending on whether or not it is bound to CD4. When trimeric Env is in the unliganded 
state, it is in a pre-fusion “spike” conformation with the V1/V2 loops located close to the 
apex of the spike82–84. However, this “spike” state breathes with some conformations within 
the equilibrium potentially available for binding to a wide range of antibodies, and others 
available only to a restricted set of (relatively broadly) neutralising antibodies85. Describing 
how neutralising antibodies bind to their epitopes on Env in its different conformational 
states can partially explain differences in sensitivity to neutralisation: Envs of viruses that are 
highly resistant are thought to spend more time in a low range of closed, pre-fusion 
conformations while sensitive viruses spend more time in open conformations86. With 
regards to the CD4 binding site at least, it was shown that bnAbs can generally bind Env in 
both open and closed conformations while poorly neutralising antibodies were shown to 






























1.2.6 The HIV-1 entry process 
  
CD4+ T lymphocytes and macrophages are the primary target of HIV-1. While the gp120 
subunit is responsible for attachment to target cells via CD4, the gp41 region mediates fusion 
between viral and target cell membranes87.  After binding of gp120 to the CD4 receptor, the 
trimer undergoes major conformational changes. The formation of a bridging sheet between 
the inner and outer gp120 domains exposes the co-receptor binding site on the virus to 
accommodate binding to the co-receptor on the surface of the target cell (either CCR5 or 
CXCR4). The fusion peptide located on the N-terminus of gp41 is then inserted into the 
target cell membrane and the six helical hairpin structure that is then formed facilitates fusion 
of the viral and target cell membrane (Fig 1.4)8.  
 
Figure 1.3 The model of the different conformations of Env. HIV-1 Env continually fluctuates between 
closed (a, c) and (b, d) open conformations. Coordinates for the gp120 core are shown in red ribbons in 
figures a and b while the predicted locations of the gp120/gp41 interface are indicated by linked cyan 
spheres, whereas V1/V2 loops are indicated by red spheres. In figure c and d gp120, gp41, and CD4-binding 








The number of trimers on the surface of Env can affect entry efficiency. Brandenberg et al. 
(2015) designed a study to define the number of trimers per virion required for viral entry 
(Env stoichiometry)88. They analyzed 11 HIV-1 isolates of differing subtypes, Env 
conformational states (open or closed) and co-receptor tropism using both experimental and 
modeling approaches. They reported that Env stoichiometry differed between isolates and 
ranged between 1-7 trimers. Higher stoichiometry was associated with reduced infectivity 
and entry kinetics88. However, for viruses with poor entry capacity, a high stoichiometry 
rescued its infectivity potential.  
 
1.2.7 The Antibody response to HIV-1 in natural infection 
  
Antibodies to HIV-1 can be broadly divided into three groups7 based on their function. These 
include non-neutralising, narrowly neutralising and broadly neutralising antibodies (bnAbs). 
Non-neutralising antibodies are directed against Env but fail to neutralise the virus because 
they usually bind epitopes that are not presented on the functional spike. However, these 
Figure 1.4 The HIV entry process. (A) The HIV-1 gp160 Env exists as a trimer made up of gp120 and gp41 
heterodimers (B) The initial contact is through the viral CD4-binding site which binds to host cell CD4 
receptor (C) Binding of CD4 leads to rearrangement of the trimer thus exposing the Co-receptor binding site 
(CoRbs) to allow binding to the co-receptor (CCR5 or CXCR4). The fusion peptide is formed and inserted 
into the host membrane (D) The viral and host membranes fuse, leading to the formation of a six-helix bundle 
and the virus completes entry into the host cell220.  
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antibodies may still possess antiviral properties by activating effector cells such as natural 
killer cells (NK cells) through their Fc receptor89. The importance of the non-neutralising 
antibody response in preventing acquisition of HIV-1 was made evident in the RV144 
vaccine trial90.  
The humoral response to HIV-1 infection develops within approximately a week of 
detectable viremia in the form of antibody-antigen complexes91. This is followed by 
production of antibodies targeting gp41. Anti-gp120 antibodies (targeting the V3 loop) can be 
detected a few weeks later92. However, these early antibodies are non-neutralising and it 
takes about 3 months for neutralising antibodies to be produced. In natural infection, the 
appearance of neutralising antibodies does not coincide with viral clearance93. This is 
possibly due to the constant viral escape from the antibody response42. Antibodies can block 
HIV-1 through multiple pathways. They can bind directly to the cell-free virus preventing 
viral entry into cells as well as work in conjunction with effector cells through the Fc receptor 
to block cell to cell spread of the virus92. 
 
1.2.7.1  Narrowly neutralising antibodies 
!
Narrowly neutralising antibodies usually neutralise only the virus that induced them, 
suggesting that they target the variable regions of the viral envelope protein such as the 
V1/V2 loop94.!Also known as autologous neutralising antibodies, they can only be detected 
about 3 months after infection. The production of these antibodies puts considerable pressure 
on the virus leading to rapid viral escape over time40,42.!As such, the antibody specificities 
evolve over time as the virus changes. The host may gain additional specificities targeting 
different epitopes at conserved sites that are newly available due to changes in the Env driven 
by antibody pressure94,95.!
!
1.2.7.2 Broadly neutralising antibodies (bnAbs) 
!
Broadly neutralising antibodies are relatively rare nAbs produced by a proportion of 
chronically infected individuals and are capable of neutralising a broad spectrum of HIV-1 
strains50. These antibodies usually target regions that are relatively conserved. A number of 
! !
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bnAbs have been isolated and characterised. They target numerous sites on Env with varying 
degrees of breadth and potency (Fig 1.5).  
1.2.7.2.1 The CD4 binding site (CD4bs) bnAbs 
!
The CD4bs is an attractive target in vaccine development as it is crucial for viral entry and 
therefore, is likely under functional constraints. Antibodies targeting the CD4bs are 
commonly elicited suggesting that these antibodies may be relatively easy to elicit upon 
vaccination 71.  The mAbs VRC0196 and N697 that target the CD4 binding site are some of the 

























Figure 1.5: Targets of bnAbs on HIV-1 Env trimer.  The colours highlighted represent the different 
epitopes targeted by some commonly studied bnAbs. CD4-binding site is shown in red, V1/V2 in purple, the 
V3/Asn 332 glycan patch in green, the gp120/gp41 interface in wheat and MPER in black. Adapted from 






The membrane proximal external region (MPER) on gp41 is an attractive target as it plays an 
important role in fusion and the epitope is linear and conserved100. However, access to MPER 
is restricted in the ‘closed’ pre-fusion state which means immunization with closed trimer is 
not likely to induce anti-MPER antibodies101,102.   10E8103 binds MPER and is capable of  
neutralising more than 90% of HIV-1 viruses tested with exceptional potency, whereas, 
4E10104 and 2F5105 exhibit moderate breadth and potency. One of the challenges faced by 
inducing MPER antibodies is autoreactivity. The epitopes targeted by 4E10 and 2F5 mimic 
conserved self-antigens106. This indicates that responses targeting these epitopes are deleted 
due to immune tolerance. However, by characterising 177 sera samples from HIV+ 
individuals, Jacob et al. (2015) reported that MPER antibodies were major contributors to 
neutralisation breadth suggesting that autoreactivity was not critical to the elicitation of these 
antibodies107. 
!
1.2.7.2.3 The V3/glycans bnAbs 
!
The V3 loop is a target for narrowly neutralising antibodies as viruses with exposed V3 loops 
are highly sensitive to neutralisation108. However, some of the most potent bnAbs are directed 
against the glycans at the base of the V3. This family includes PGT121-123, 125-128, 130, 
131 and 135 and 10-1074109,110. bnAbs against the V3 glycans have shown remarkable 
efficacy in NHP models and human trials. Immunization with PGT121 protected macaques 
from infection111 and the antibody 10-1074 was capable of controlling viremia in ART naïve 
HIV-1 infected individuals112.   
 
1.2.7.2.4 The V2/apex bnAbs 
!
The V2 loop is highly variable. However, a conserved surface within this region forms the 
V2/apex epitope that is the target of some bnAbs. PG9 and PG16 are conformation dependent 
mAbs that bind a quaternary epitope on the V2 apex70. They are also dependent on surface 
glycans specifically at amino acid position 160 (N160)81, but do not appear to bind directly to 
the glycan113. These two antibodies can neutralise up to 80% of HIV-1 isolates each70. 
Unfortunately, antibodies against this region are often deleted during antibody development 
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as they usually possess an unusually long and anionic complementarity-determining region in 
the heavy chain 3 (CDRH3)114. The long CDRH3 allows the antibody access to epitopes 
shielded by the dense glycosylation in this region115. 
1.2.7.2.5 The gp120-gp41 interphase 
!
Antibodies targeting this site are dependent on distinct glycans that lie at the interphase of 
gp120-gp41. 8ANC195 recognizes glycans at positions 230, 234 and 276116, PGT151 binding 
relies on glycans 611 and 637117 while 35O22 targets 8855. Interestingly, escape from another 
interphase antibody CAP248 2B, resulted in a viral phenotype that was exceptionally 
sensitive to MPER antibodies. These escape mutations can be used in vaccine design to make 
the MPER more accessible and immunogenic118.!
1.2.8 Neutralising antibodies can protect against HIV-1 challenge 
!
Several studies have been carried out to further explain the importance of antibodies. B cell 
depletion studies in NHPs suggested that antibodies had a role to play in reducing viral load 
and disease progression119,120, although not in African green monkey hosts121. There is 
limited evidence that this may also be true in humans. Huang et al. (2010) reported an 
increase in viremia and the emergence of a neutralisation sensitive viral population after 
depletion of B cells in a chronically infected individual122. These findings tend to support the 
role of antibodies in controlling HIV-1 in natural infection.  
 
The potential of neutralising antibodies in preventing HIV-1 was clearly illustrated by 
passive immunisation studies in NHPs and mice. Administration of neutralising antibodies 
before viral exposure was found to protect macaques against SIV/SHIV infection123–125 and a 
combination of two mAbs (2F5 and 2G12) protected NHPs from SHIV challenge4. 
Immunisation with bnAbs such as PGT121111 and PGT126126 alone or bnAb combination of 
VRC01, VRC01-LS, 10-1074 and 3BNC1176 also protected against infection. In a recent 
study, humanised mice were protected from repeated intravaginal HIV-1 challenge after 
immunisation with the CD4bs antibody b12. The authors also reported that treatment with 
PGT126 offered sterilising protection in these mice127. 
 
Although the antibody response to HIV-1 is complex, it is nevertheless an important 
functional response. nAbs have an enormous potential for therapy of HIV-1 as evidenced by 
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the studies briefly mentioned above. However, rapid and constant escape from antibodies 
poses a challenge that still needs to be overcome before these interventions can be 
introduced. Escape from bnAbs such as 2G12128,129, 10-1074112, VRC01130 and 3BNC117131 
used as therapy in HIV+ individuals has been demonstrated.  
1.2.9 HIV-1 escapes the neutralising antibody response 
!
Although HIV-1 isolate specific neutralising antibodies could be detected quite early on in 
the course of an HIV-1 infection132, this response is followed by clearance of sensitive 
viruses and the emergence of a resistant population42. The constant escape from nAbs any 
time partly explains the immune system’s inability to control the infection. Additionally, 
antibody pressure contributes to the rapid evolution of the virus and the extensive variation 
observed in the env gene (see 1.2.1)40.  This poses a problem for vaccine developers, as 
escape from vaccine-elicited responses would greatly reduce the benefit of the vaccine. A 
vaccine that targets multiple independent epitopes on the virus would ensure vaccine 
coverage. This may be achieved by using multivalent vaccines that exhibit breadth of 
coverage133. In the case of HIV-1 therapy, passive immunisation with combinations of bnAbs 
rather than single specificity bnAbs, would also limit the likelihood of escape134.  
 
1.2.9.1 Mechanisms of HIV-1 escape 
!
HIV-1’s tolerance for env sequence variability while retaining function makes it adept at 
escaping the neutralising antibody response135.  The various mechanisms of viral escape have 
been described in a bid to overcome this challenge. Single point mutations on the env (even 
outside the antibody epitope) have been shown to affect susceptibility to neutralisation136–138.  
1.2.9.1.1 The glycan shield 
!
Even though the glycans on the surface of gp120 are a critical target for nAbs, they also play 
a crucial role in the antibody evasion of HIV-1. They acts as a shield against nAbs by 
masking important epitopes on the envelope thereby rendering the virus less susceptible to 
neutralisation42,44 Due to antibody pressure, the positions and numbers of PNGs varies 
thereby forming a continuously evolving ‘glycan shield’44.  More specifically, the removal, 
addition or shifts at key glycan positions have been shown to affect antibody neutralisation 
(as a single glycan occludes a volume roughly equivalent in size to the V3 loop)5,11. In a 
! !
 17 
longitudinal study, an important glycan site shifted from position N332 to N334 in two 
patients which abrogated sensitivity to neutralisation by broadly cross-neutralising 
antibodies44. This eloquently captured the evolution of the virus in response to the pressure 
exerted by neutralising antibodies. In another study, a loss of glycan at position N241 created 
a ‘glycan hole’ rendering the virus sensitive to neutralisation139.  
1.2.9.1.2 Conformational masking 
!
Important antibody targets could also be ‘hidden’ from neutralising antibodies as the 
Envelope trimer retains a ‘closed, pre-fusion’ conformation that only becomes unmasked 
during entry after CD4 binding. This allows the virus to maintain receptor binding while 
avoiding antibody neutralisation84,141. Variation in variable loop length (V1/V2) has also been 
associated with neutralisation: Longer V1/V2 loops are thought to mask important epitopes 
targeted by CD4bs antibodies thereby making viruses more neutralisation resistant142,143.  
 
These evasion mechanisms contribute to the persistence of HIV-1 in the face of functional 
antibody responses that are often vigorous and sustained.  
 
1.2.10 Evidence that HIV-1 is evolving to become more resistant to neutralisation 
!
Several studies suggest that HIV-1 is evolving towards a more neutralisation resistant 
phenotype. Bunnik et al. (2010) compared neutralisation sensitivities of subtype B isolates 
from Dutch cohort studies carried out either early in the epidemic or more recently. They 
reported increased neutralisation resistance as the epidemic progressed especially towards 
CD4bs antibodies144. Another study validated this finding by comparing subtype B isolates 
from French individuals at 3 different time points spanning 20 years11. Rademeyer et al. 
(2016) compared subtype C viruses from three-time points and also reported enhanced 
resistance in the later isolates to the bnAbs 4E10, PG9 and VRC01. In another study, 34,000 
HIV-1 sequences from samples collected at different time points were analysed and the 
researchers reported a drift towards increased resistance to a broad range of bnAbs145. This 
may pose an increasing problem in the design of antibody-based HIV-1 interventions. 




1.2.11 Categorising viruses based on neutralisation sensitivity: a tier approach 
!
Viral isolates may be grouped into different tiers (1 to 3) based on their neutralisation 
sensitivity patterns. Tier 1A and 1B are described as highly sensitive, tier 2 moderately 
sensitive and tier 3 comprises of viruses with a highly resistant phenotype. Tier classification 
has been done by testing viruses against neutralising antibodies present in serum/plasma of 
HIV-1 positive individuals146–148. Seaman et al. (2010) tested 109 virus isolates representative 
of the circulating strains in the population against 7 plasma pools (also representative of the 
circulating subtypes). One or more of the pools could neutralise most of the viral isolates 
tested. Furthermore, they reported increased neutralisation if the virus was subtype matched 
to the plasma pool tested i.e. subtype C viruses were more sensitive to the subtype C plasma 
pool146. Viruses with similar neutralisation profiles were grouped using k-means clustering 
into subsets representative of distinct tiers of neutralisation sensitivity. However, it is 
important to note that tier definition is partially dependant on the sera or panels of sera 
used146.   
 
There is evidence suggesting that the increased susceptibility to neutralisation of tier 1 
viruses could be due to their Env trimer sampling the open conformation more readily thus 
making epitope accessibility easier for antibodies85. So far, a number of the vaccine 
candidates tested have elicited antibodies that neutralise only Tier 1 isolates149,150. However, 
the majority of the circulating viruses tested belong to tier 2. Subsequently, vaccine efforts 
are likely to focus on eliciting tier 2 responses. Tier 3 viruses, although few in number are 
highly resistant and could offer valuable insight into vaccine design. This subset will be the 
focus of my study.  
1.2.12 Does antibody resistance/escape affect Env function and fitness? 
!
Despite Env’s sequence plasticity to escape the immune response, it still needs to retain its 
function.  We hypothesize that mutations away from wild type virus could incur some 
reduction in fitness of the virus. Rapid reversion to the wild type of some immune escape 
mutations upon transmission suggests fitness costs may be significant9.  For instance, long 
variable loops and increased glycosylation density are features associated with resistance and 
chronic infection68. However, these features are reversed in transmitted viruses (shorter loop 
lengths and fewer glycosylation sites)151 rendering the transmitted virus more sensitive to 
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neutralisation by one report151, but not another report152. Together, this suggests that these 
changes in variable loop characteristics and glycosylation may have an impact on viral 
fitness.  Therefore, the most effective immune responses may be those targeting the regions 
of the virus where escape mutation inflicts the largest fitness cost to the virus. Such 
knowledge could be used to rationally design more effective vaccines. 
 
Due to the crucial role Env plays in viral entry and as a major target of the immune response, 
a number of studies have evaluated the effect of changes on env sequence and its impact on 
viral fitness. One study investigated the effect of mutations on antibody epitopes on HIV-1 
entry efficiency (infectivity)88.  This study reported that reconstitution of the N160 glycan in 
a virus that naturally lacks N160 led to a 4-fold increase in infectivity. The authors also 
created 3 variants of a tier 2 virus, JR-FL, with mutations mimicking escape mutants. A JR-
FL D664N escape mutant that is resistant to the MPER antibody 2F5, a second JR-FL 
V549M N554D mutant which has highly increased resistance against the entry inhibitor T-
20, and a third JR-FL mutant with point mutations at positions N332S, P369L, M373R and 
D664N which rendered it resistant to the bNabs PGT128, 2G12, b12 and 2F5. While the 2F5 
mutant infected just as well as the wild-type (WT), the T-20 and multiple escape mutant 
exhibited reduced infectivity (9% and 19% respectively)88. These findings indicate that even 
a single amino acid change, potentially driven by antibody escape, has an appreciable effect 
on Env function. It is important to note, however, that mutations on other regions of the virus 
such as Gag contributes to much greater fitness impairment. Escape from cytotoxic T 
lymphocytes led to mutations on Gag p24 that incurred appreciable fitness costs compared to 
Env153.  
 
In addition, other studies have been conducted to investigate whether viral escape from the 
autologous antibodies targeting Env could lead to the selection of viral variants with overall 
reduced replication potential. While there is evidence to suggest that the constant escape due 
to immune pressure may sometimes lead to impaired viral fitness and replication, the reports 
have been inconclusive154. For instance, Sather and colleagues studied one donor whose sera 
contained broadly neutralising activity directed against the CD4bs. They demonstrated that 
viral escape from this response negatively impacted viral replication155. A later study 
demonstrated that while escape from VRC01 was associated with impaired fitness, 
compensatory mutations restored the ability of the virus to replicate156. However, it could be 
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argued that viral escape/resistance from a polyclonal response comprising multiple antibody 
specificities could have a much greater impact on viral replicative fitness compared to 
monoclonal antibody (such as VRC01 in the study above) that target a single site.  Studying 
the effects of antibody resistance on Env function, viral fitness and eventually viral evolution 
may reveal Env properties that can be evaluated and exploited for vaccine and therapy 
development.  
 
1.2.13 Do highly resistant viruses (tier 3) have decreased entry efficiency? 
!
Tier 3 isolates are underrepresented even in viruses from chronically infected 
individuals143,146. In a sense this is surprising because viruses at the chronic phase are 
constantly escaping antibody, which should presumably lead to the emergence of highly 
neutralisation-resistant viruses. We hypothesize that these highly resistant strains could have 
diminished entry (due to changes on Env) and are out-competed by other less resistant but 
ultimately fitter viruses during an infection. In other words, a reduction in fitness reduces the 
opportunities for highly neutralisation-resistant viruses to emerge during chronic infection. 
As the neutralising antibody response provides positive selective pressure favoring viral 
escape, the envelope protein is not infinitely plastic and mutations can carry fitness costs. 
This is supported by the evidence that suggests that the transmission favours viruses that are 
more sensitive to the neutralising antibodies of the donor151,157.  
This thesis will determine if there is a relationship between resistance and viral entry, which 
in this study will be used as a component of viral fitness. While the virus’ mechanism of 
resistance is not clear and may vary from virus to virus, we hypothesize that due to their 
resistance phenotype, they may exhibit decreased entry efficiency and this might explain their 









1.3 Study rationale 
!
The presence of circulating highly resistant viruses could greatly impede antibody based 
vaccine and therapy efforts. For this reason, it is important to study and characterise these 
highly resistant isolates. Neutralisation resistance may be explained by absence of key Env 
epitopes and in some instances by conformational changes that make these epitopes less 
accessible to nAbs.  Envs of highly resistant viruses have been shown to exist in a low range 
of “closed” conformations which inhibit nAb binding86,158. This might coordinately inhibit 
key virus-target cell interactions such as co-receptor binding. Thus, it is important to 
understand if Env retains its full functionality in the context of such resistance.  Differences 
in viral fitness between HIV-1 isolates have been sometimes mapped to Env159–162. As Env is 
the most diverse HIV-1 protein163, these findings indicate that differences in viral fitness 
attributed to Env might influence viral evolution, transmission and disease progression160,164–
166. The functional and genotypic changes of the env of resistant viruses as compared to less 
resistant viruses are explored in this study. We hypothesized that a highly resistant Env has 
impaired entry and that this mechanism that could explain why there are fewer tier 3 viruses 


















1.4 Study aims and objectives 
!
The aim of this study is to characterize the viral Env protein of highly resistant viruses (tier 3) 
and determine whether there are functional differences between those viruses and more 
sensitive isolates. We seek to understand whether these differences, if present, could explain 
the resistant phenotype and the apparent underrepresentation of tier 3 viruses in the 
population. 
 
1.4.1 Specific objectives 
!
1. To describe the Env differences in Env characteristics between tier 3 viruses and more 
sensitive viruses. 
 
We compared genotypic characteristics associated with resistance such as variable loop 
characteristics and glycosylation patterns between viruses with differing neutralisation 
sensitivities. The predicted sites of glycosylation, loop length and charge were determined 
using online prediction tools. 
 
2. To determine whether differences in Env function exist between tiers by comparing 
entry efficiencies and susceptibility to entry inhibitors. 
We hypothesized that resistant viruses have less favourable phenotypic characteristics 
affecting entry such as CD4 and CCR5 binding capacity. Pseudoviruses were generated and 
used for single-cycle entry assays to measure entry efficiency. As all the pseudoviruses 
shared the same backbone, any changes identified were assumed to be influenced by Env and 
not other viral proteins.  
We also measured the susceptibility of these viruses to entry inhibitors that block binding to 
CCR5 in subtype C and CRF02_AG viruses and compared the differences between the two 











2.0 Material and Methods 
!
!
The main aim of this study was to investigate the genotypic and functional differences 
between Envs of differing neutralisation sensitivities. Resistance was defined using publicly 
available data of within-subtype neutralisation by a large panel of sera143,147. Within-subtype 
data was considered a better indicator of resistance as neutralisation is greater when a virus of 
a given clade is tested against plasma from an individual infected with that same clade147,167–
169. This suggests that epitopes of viruses that belong within the same clade are likely to share 
similar epitopes compared to cross-clade serum/virus combinations.  Thus, within-subtype 
neutralisation will likely give a better picture of the sensitivity of a virus to antibodies 
targeting wider range of epitopes than using subtype-mismatched serum/virus pairs. 
Importantly, using a large panel of sera/plasma likely increases the nAb specificities present 
increasing the chances of neutralising a large set of viruses.  
• Selection of viruses used in the study 
We evaluated genotypic and neutralisation properties of 89 Env clones belonging to two 
HIV-1 subtypes; C (n=81) and CRF02_AG (n=8). These were selected as the Env clones 
were readily available for use in the laboratory and their neutralisation sensitivity phenotypes 
have been well defined143,147. For the first analysis, variable loop (V1-V5) characteristics 
such as loop length, glycan density and net charge were compared to investigate the features 
associated with resistance.   
For the second analysis, a panel of 16 subtype C Env clones were selected which represented 
a range of neutralistion resistances, and similar genotypic features (Table 2.1). All eight 
CRF01_AG viruses were used (Table 2.2).  Pseudoviruses generated from these clones were 
used to evaluate if neutralisation resistance/tier 3 viruses had different functional Env 
characteristics as measured by entry efficiency and susceptibility to entry inhibitors assays. 
2.1 Summary of tiered classification of subtype C and CRF02_AG viruses 
!
The viral isolates used in this study had already been classified into tiers based on their 
neutralisation sensitivities in previous studies143,146. For tier classification, Rademeyer et al. 
(2016) tested clade C serum samples from 54 ART-naïve, chronically infected South African 
HIV-1+ individuals for breadth and potency against 3 subtype C PSVs, a consensus subtype 
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C and B virus and a subtype A PSV. A panel of 30 sera exhibiting varying breadth was then 
selected from this to be tested against subtype C Env clones. Viruses were grouped into tiers 
(1B, 2 or 3) based on their average Log10 ID50  (ID50 is defined as the serum dilution at which 
50% of viruses are neutralised) titres using the k-means clustering method as described by 
Seaman et al. (2010) Tier 1B and tier 3 formed highly significant and robust clusters with 
every other virus in between classified as tier 2. This process was reproduced when 
neutralisation sensitivity of each virus against all 30 sera was measured as geometric mean 
ID50 titre143. The geometric mean ID50 values for the CRF02_AG viruses used in this study 
were determined by Jacob et al. (2012) using a pool of CRF02_AG plasma147.  Seaman et al. 
(2010) categorised these CRF02_AG viruses into tiers however, there was a discrepancy in 
tier ranking as some of the viruses ranked as tier 3 by Seaman et al., (2010) were found to be 
sensitive by Jacob et al. (2012)146,147. This discrepancy might be because the plasma pools 
used in Seaman’s study did not contain high levels of CRF02_AG specific antibodies. The 
CRF02_AG plasma pool in Seaman’s study was not specifically selected for higher 
neutralisation activity. In contrast, in the Jacob et al.’s (2012) study, they selected for 
samples likely to have come from individuals with longer HIV-1 infection prior to sample 
collection170, which selected for those with higher neutralisation activity. Jacob  et al (2012) 
proposed that the low neutralising activity CRF02_AG blood plasma pool used by Seaman  et 
al. (2010) artificially pushed some of the CRF02-AG viruses analysed into the tier 3 
category.  Due to the inconsistency in tiering of CRF02_AG viruses, I used the geometric 
mean ID50 values to reflect neutralisation sensitivity. In addition, all serum/plasma samples 
used in these three studies were from chronically infected individuals thereby increasing the 
chances of including good neutralisers thereby increasing our chances of identifying resistant 
viruses selectively.  
 
Env clones used in the phenotypic assays were selected from these subtype C and 
CRF02_AG viruses. All subtype C tier 3 viruses that were available to me were included in 
the study. Thereafter, viruses were randomly selected to cover a range of neutralisation 









 Place of origin: Tanzania (TZ); South Africa (SA);  
b Infection Staging: I (Intermediate) is Fiebig stage III/IV; and E (Early) is Fiebig stage V/VI. All samples were 




a Infection Staging: E (Early) is Fiebig stage V/VI. Fiebig staging as defined by Fiebig et al. 2003. Geometric 






















CA146_H3_3 1B SA 26 days E 2009 68    5    4    
CAP174.1.06_F3_1B 1B SA V E 2005 65    4    2    
CAP301.2.00_C3.20 1B SA 4 weeks E 2008 65    2    2    
569-F1_37_10 2 TZ V/VI E 2001 69    5    -2    
CAP307.2.00_24_1 2 SA 30 days E 2008 68    8    0    
CAP306.2.00_F9.1 2 SA 2 weeks E 2008 75    9    0    
CAP317.2.00_D4.10 2 SA 7 weeks E 2008 66    5    -2    
CAP382.2.00_D7.19 2 SA 7 weeks E 2010 61    4    -3    
CAP363.2.00_10_3 2 SA 37 days E 2009 69    7    -1    
CAP225.1.06_A2_18 3 SA III I 2005 75    6    1    
CAP237.1.22_B2_2_39 3 SA III I 2007 70    5    2    
CAP291.2.00_H2.15 3 SA 11 weeks E 2008 74    6    -1    
Ko243_H6.3 3 SA 58 days E 2009 88    5    4 
541-F1_A7_2 3 TZ 47 days E 2001 68    5    1    
98-F4_H5-13 3 TZ V E 2001 71    5    1    












T278_50 23 Cameroon E 75    7    2    
T253_11 29 Cameroon E 65    5    1    
T251_18 53 Cameroon E 72    6    0    
T33_7 67 Cameroon E    
T255_34 402 Cameroon E 68    7    1    
928_28 139 Cote D'Ivoire E 70    6    1    
T257_31 180 Cameroon E  74    5    2    
T250_4 314 Cameroon E 61    3    5    
Table 2.2 Description of CRF02_AG viruses used in entry efficiency and inhibition assays 
!




2.2 Genotypic characterisation of viruses 
2.2.1  Variable loop characterisation 
!
Variable loop length, glycan density and net charge were determined using a web tool 
available on the Los Alamos HIV-1 sequence database 
(https://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR/index.html). An alignment 
of HIV-1 sequences is input and variable loop boundaries/postions are selected based on a 
refrence sequence (HXB2). The length of the V1 loop (position 131-157), V2 (position 158-
196), V3  (position 296-331), V4 (position 385-418) and V5 (position 460-469) were 
measured. N-linked glycosylation sites were defined as the sequence motif  N-X-T/S except 
when X is a proline. The net charge was determined as the sum of amino acid charges. The 
amino acids lysine (K), arginine (R)  and histidine (H) were computed as positively charged 
and amino acids and aspartic acid (D) and glutamic acid (E) as negatively charged. 
2.2.2 Glycan analysis 
2.2.2.1 Univariate analysis 
!
Potential N-glycosylation sites (PNGs) were tallied using the N-glycosite web tool 
(https://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html). Only subtype C 
viruses were included in this analysis. 200 subtype C sequences classified as either tier 1B, 2 
or 3143 were aligned separately and uploaded into the tool. Only sites that occurred in 20-90% 
of the sequences were tallied. This threshold was chosen to make sure that there would be 
enough viruses in the groups positive for the PNG and negative for the PNG to give 
reasonable statistical power in the analysis. In instances where a glycan site was conserved in 
one tier and not the other, the glycan sites were manually tallied for that tier in order for us to 
make comparisons. Once again, HXB2 reference sequence was used to number poistions. 
2.2.2.2 Bayesian model averaging 
!
To investigate which PNGs had the most influence on neutralisation resistance, linear 
regression models were fit using each PNGs selected above as a predictor. To determine the 
quality of each model relative to the other models and select the “best fit” ones, the Akaike 
information criterion (AIC) was used. Bayesian model averaging was then used to combine 
the estimates from the models selcted by AIC into one final model171,172, with assitance from 
Dr. Michael Schomaker, CIDER, UCT). This method enables us to report the most stable 
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estimates while taking into account modelling uncertainty. The result of this analysis is 
presented as the posterior effect probability of each PNGs. This value is the probability that 
the regression model coefficients are not equal to zero which indicates that there is an effect. 
The higher the probability, the more evidence to support that a PNGs has an effect on 
neutralisation.  
2.2.3 Monoclonal antibody analysis 
!
We analysed sensitivity of subtype C viruses to commonly tested mAb. The epitopes of mAb 
have been well studied. Therefore, by carrying out this analysis, we may be able to determine 
the epitopes that drive resistance in tier 3 viruses. This analysis is important as mAbs are 
important for use as potential therapeutic and preventative interventions. All the data 
concerning the sensitivity of individual viruses to particular monoclonal antibodies used in 
this analysis was obtained from CATNAP, a web based tool available on the Los Alamos 
HIV-1 sequence database  
(https://www.hiv.lanl.gov/components/sequence/HIV/neutralization/index.html). To compare 
neutralisation sensitivities to bnAbs of tier 1B, 2 and 3 to the commonly studied bnAbs, 200 
subtype C viruses that had bnAb data were used. Very few bnAbs were tested on tier 3 
viruses. Therefore, only the nine bnAbs that had data for all tier 3 classified viruses were 
included in the analysis. Neutralisation sensitivity was represented as the concentration of 
antibody at which 50% of the viruses are neutralised (geometric mean IC50) . 
!
2.3 Production of pseudoviruses: Cell lines used  
!
Pseudoviruses (PSVs) were generated by transfecting the HEK293T cell line obtained from 
the National Institute of Health (NIH) AIDS Reagent Program. HEK293T is a human cell 
line commonly used for the expression and production of proteins by transfection with 
plasmid DNA. Single cycle infectivity assays173 were conducted using the TZM-bl cell line 
obtained through the National Institute of Health (NIH) AIDS Reagent Program- Division of 
AIDS, NIAID from Dr John C. Kappes and Dr Xiaoyun Wu. This is a HeLa cell line that has 
been engineered to express CD4 and CCR5 which allows for HIV-1 entry into the cell174. In 
addition, the cells have a firefly luciferase reporter gene under the control of a HIV-1 long 
terminal repeat (LTR)175. Transcription of the viral proteins is initiated when the viral Tat 
protein binds to the LTR. Viral entry, reverse transcription, integration and expression of the 
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viral Tat protein results in expression of the luciferase reporter which is quantified by 
measuring luminescence after the addition of a luciferase detection reagent (Promega, 
Madison USA) to the infected cells176. Both cell lines were maintained in culture media 
supplemented with 5% fetal bovine serum (FBS). However, assays were conducted in culture 
media supplemented with 10% FBS. Culture media contains Dulbecco’s Modified Eagle 
Medium (DMEM) (Sigma chemical company, Schnelldorf, Germany) supplemented with 10 
µg/mL of gentamicin, 25mM HEPES, 1% non-essential amino acids, 10 µg/mL pen-strep. All 
cultures were maintained in a humidified incubator at 37°C and 5% carbon dioxide. All cell 
culture incubation steps in this study were carried out in a humidified incubator at 37°C. 
Cells were grown in monolayers in tissue culture plates and passaged every 2 days.  Cells 
were passaged by first aspirating out the media and then washed with 5mL Dulbecco’s 
Phosphate-Buffered Saline (DPBS) without Calcium or Magnesium. Thereafter, 2mL room 
temperature 1X trypsin-EDTA (0.25% trypsin, 1mM EDTA)  (Invitrogen, Dramstadt, 
Germany) solution was added to the cells and incubated at 37°C for 2 minutes in order to 
detach the adhered cells from the plate. The trypsin was inactivated by adding 8ml media 
with FBS to the plate and the cells carefully washed off and transferred to a 50ml conical 
tube for centrifugation at 1200rpm for 5 minutes. The pellet was then resuspended in 5ml of 
media and cells were counted using a haemocytometer.  Cells were maintained at a density of 
1 x 106 /ml until use in assays. 
2.4  Env DNA preparation (transformation and plasmid purification) 
!
Cloned HIV-1 envelope constructs for the subtype C and CRF02_AG viruses were used to 
generate PSVs. The constructs consists of the env gene cloned into a pcDNA expression 
vector obtained from the National Institute of Health (NIH) AIDS Reagent Program 
(http://www.aidsreagent.org/pdfs/11673_tab1.pdf) and Rademeyer et al.(2016). To generate 
more plasmid, the constructs were transformed and grown in Stbl 3 competent cells. 25 µL of 
Stbl 3 competent E. coli cells were thawed on ice and 200 ng of Env plasmid construct was 
added to the cells. The cells were incubated on ice for 30 minutes. Transformation occurred 
through the heat shock method. After the incubation on ice, the cells were incubated in a 
420C water bath for 30 seconds and quickly returned on ice for 2 minutes. 200 µL of cell 
recovery media (S.O.C media) (Sigma chemical company, Schnelldorf, Germany) was added 
to the cells. The cells were then incubated in a shaking incubator (320C, 250rpm) for 1.5 
hours. The cells were then plated on agar plates supplemented with 100 µg/ml ampicillin and 
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left overnight in a 320C incubator. The next day, single colonies were picked and grown in 
5ml Luria-Bertani (LB) broth overnight at 320C. Cells were pelleted by centrifugation and 
plasmid extraction was carried out using the GeneJet™ Plasmid Miniprep Kit (Thermo 
Fischer Scientific, Massachusetts, USA). After successful extraction, the plasmid 
concentrations were determined using a nanodrop 2000 spectrophotometer (Thermo 
Scientific, Massachusetts, USA).  
 
2.5  Pseudovirus generation  
!
Pseudoviruses (PSVs) lack a complete genome and are thus incapable of producing infectious 
progeny viruses. For this reason, they are suitable for single round infection assays. To 
generate PSVs, HEK293T cells were co-transfected with an env clone of interest and a 
plasmid containing a HIV-1 subtype B genome; pSG3Δenv177. pSG3Δenv contains all 
functional viral genes, except that the env gene contains a 4 base pair insertion which renders 
it defective. Using the same viral backbone for all PSVs meant that any differences in 
functional assays would be attributed to Env. The pSG3Δenv reagent was obtained through 
the NIH AIDS Reagent Program, Division of AIDS, NIAID, and NIH from Drs. John C. 
Kappes and Xiaoyun Wu. HEK293T cells were seeded at 1 x 106 cells into a T25 culture 
flask in a final volume of 5ml 10% supplemented media. For each clone, 1334µg plasmid env 
DNA was added to 2667µg pSG3Δenv backbone DNA and the volume adjusted to 35µL with 
sterile plain DMEM. XtremeGENE 9 transfection reagent (Roche) was diluted in plain 
DMEM and added to the DNA mixture. This was mixed by vortexing for 5 seconds and then 
incubated at room temperature for 30 minutes. Each mix was subsequently added directly to 
the flasks containing HEK293T cells in 5ml media and the flasks were incubated for 48h in a 
37°C, 5% C02 humidified incubator. Cell culture supernatants containing secreted PSV were 
collected after 48 hours. 
2.6  Calculating entry efficiency 
!
To determine the titre of the PSVs produced, TZM-bl cells were infected with PSVs at 
different concentrations to ascertain the dilution of supernatant at which there was 50,000 
RLUs. Infection was carried out in the presence of DEAE dextran (Sigma chemical company, 
Schnelldorf, Germany). This is a poly-cation that enhances virus infection by stabilizing 
virion adsorption to the cell membrane. PSVs were diluted 2-fold to a final volume of 50ul 
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and topped up with 100ul of 10% DMEM in a 96 well microtitre tissue culture plate. 50ul of 
TZM-bl cells were added at a final density of 1 x 104 per well. Eight cell control wells were 
included in each plate by adding 10% DMEM to the cells instead of virus. The plates were 
incubated for 48 hours at 37°C, 5% CO2! .!After the 48 hours elapsed, 100µl of supernatant 
was removed from each well and replaced with 100µl Bright-Glo luciferase substrate, 
dissolved in Bright-Glo subtrate/lysis buffer (Promega, Madison, USA). The plates were 
incubated for 2 minutes in the dark and 100µl of the mixture was transferred into an opaque 
black plate to be read on a VERITAS MicroPlate luminometer (Promega, Madison, USA). 
Wells with RLUs greater than 2.5 times the average cell control value were considered 
positive. To determine entry efficiency, RLU measurements for each PSV were normalized 
to the amount of Reverse Transcriptase (RT, see section 2.6) activity detected in the sample 
and expressed as RLU/pg RT.!Infectivity was determined from two independent experiments 
using two different PSV stocks for each isolate.!!!
!
Figure 2.1 Schematic of pseudovirus (PSV) generation and TZM-bl infection assay.  Co-
transfection of a plasmid containing pSG3Δenv and pEnv into 293T cells allows for the generation 
of  PSVs. Infectious PSVs infect TZM-bl and induce the expression of the luciferase reporter gene. 






2.7 Quantifying viral Reverse Transcriptase activity for infectivity assays. 
2.7.1  Virus isolation 
!
Supernatant containing PSVs was harvested 48 hours post transfection.  To quantify reverse 
transcriptase (RT) it was necessary to concentrate the virus particles. In this instance, we used 
ultra-centrifugation to concentrate virus particles.  An initial centrifugation step was carried 
out to remove cellular debris (2000g for 30 minutes at 40C) from the supernatant. 1mL of the 
supernatant was then transferred to an ultracentrifugation tube (Beckman coulter, 
Indianapolis, United States) and centrifuged at 100,000g for 10 minutes in an ultracentrifuge 
(Beckman Coulter, Indianapolis, United States). The supernatant was then carefully decanted 
and the pellet was stored at -800C for RT quantification.  
 
 
2.7.2 Reverse transcriptase colorimetric assay 
!
To quantify the relative quantities of PSVs produced, viral RT activity was measured using a 
colorimetric immunoassay kit (Roche Holdings, Basel, Switzerland). This assay makes use of 
RT’s ability to synthesize DNA from a template. The template/primer hybrid (poly (A) × 
oligo (dT)15) required for the reaction were supplied with the kit.  Digoxigenin (DIG) and 
biotin labelled nucleotides are then incorporated into the DNA molecule synthesized by the 
viral RT. The detection of the new DNA molecule follows a sandwich ELISA protocol.   
 
Briefly, the stored pellets were lysed with a lysis buffer (50mM Tris, 80mM potassium 
chloride, 2.5mM DTT, 0.75mM EDTA and 0.5% Triton X-100, pH 7.8; provided with kit) 
and incubated at room temperature for 30 minutes to ensure complete resuspension and lysis. 
The template/primer hybrid and nucleotides mixture was then added to the viral lysate and 
incubated for 1 hour at 37oC. The reaction mixture containing the newly synthesized DNA 
was transferred to a streptavidin coated 8-well microplate module, which will strongly bind 
to the biotin in the DNA, if reverse transcription has taken place, and incubated for 1 hour at 
37oC. The wells were then washed and an antibody to digoxigenin conjugated to peroxidase 
is added. This antibody binds to digoxigenin on the synthesized DNA molecule, if present. 
Following antibody binding, the wells were washed to remove unbound antibody and a 
peroxidase substrate, ABTS, was added. Peroxidase catalyses the cleavage of this substrate 
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into a coloured product, which was measured on an ELISA plate reader at 405nm and 
compared to a reference reading at 492nm. The absorbance at 492nm was subtracted from the 
405nm reading and this is directly proportional to the amount of RT activity in the sample. 
To determine RT concentrations, an HIV-1 RT (supplied with kit) with known concentrations 
was used as a standard. This standard was serially diluted and used to draw linear calibration 
curves. The average absorbance for replicate readings were plotted on the y-axis and the 
concentration of HIV-1 RT standards were plotted on the x-axis. The concentrations of RT 
for unknown samples were then determined by plotting the sample absorbance values on the 
y-axis and the concentrations were extrapolated from the RT concentrations on the x-axis. 
 
 
Figure 2.2 Schematic of the reverse transcriptase (RT) activity assay.  Viral RT synthesizes DNA 
labelled with biotin and DIG which is added to a strptavidin coated well. Addition of a peroxidase 
conjugated anti-DIG antibody allows for the measurement of RT activity. Image from Sigma. 
 
 
2.8  Entry inhibition assays 
!
The entry inhibitors Maraviroc (CCR5 anatgonist), PSC RANTES (CCR5 competitive 
inhibitor) and T20 (fusion inhibitor) were used to determine a virus’ dependence on  aspects 
of the entry process. These inhibitors were selected as they showed a correlation to entry 
efficiency assays in preliminary studies. Five fold serial dilutions of the inhibitors were made 
and 50ul of the dilutions were added to a 96 well tissue culture plate in duplicate. 100µl of 
TZM-bl cells with DEAE dextran were added to the wells at a final density of 1 x 104 per 
well. The plates were incubated at 370C for 30 mins. Thereafter, PSVs were added at a 
concentration that would yield 50,000 RLUs. The plates were then incubated for 48 hours. 
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100µl of supernatant was removed and replaced with 100µl of luciferase substrate and 
incubated in the dark for 2 mins. The mixture was then transferred to an opaque plate and 
luminometer readings were obtained. Antiviral activity was determined as the percentage of 
viral inhibition in experiment wells compared to the control wells (no inhibitor). Viral 
inhibition was plotted against the concentration of the inhibitor compound tested and a curve 
fit function was used to calculate the concentration of inhibitor at which 50% of entry is 
inhibited represented as an EC50 (GraphPad Prism software, CA, USA). 
 
2.9  Statistical analysis 
!
Statistical anayses of all data were performed on STATA (STATACorp) and GraphPad 
Prism. Graphs were generated using GraphPad Prism. EC50 values were generated using the 
curve fit function on GraphPad Prism. Prior to carrying out any tests, the Shapiro Wilk’s test 
was used to determine if data was normally distributed. Where data was normally distributed, 
a student t-test was used to calculate p-values. Otherwise, the Mann Whitney test was 
employed. In all analyses where the sample number was small, the Mann Whitney test was 
used. The median and interquartile range are shown on all dot plots. Correlations were 
performed using Pearson’s correlation (CI 95%) or Spearman’s correlation depending on the 


















3  Results 
 
 
3.1  Neutralisation profile of subtype C and CRF02_AG viruses 
!
The subtype C viruses used in this study had already been categorized by tier based upon 
their neutralisation sensitivity to a panel of subtype C-infected sera143 (Fig 3.1). Selection of 
the 16 subtype C Envs to be used in the functional assays was primarily based on 
neutralisation phenotype.  First, all tier 3 viruses were selected (red dots) for which I had 
access to clones for generating PSVs, thereafter; tier 2 (blue dots) and 1B (green dots) viruses 
were selected to represent a wide range of neutralisation sensitivities.  
 
 
Figure 3.1 Geometric mean ID50 and tier classification of subtype C viruses used in this study. 81 subtype 
C Viruses were rank ordered according to their sensitivity to neutralisation to a panel of 30 sera from 
chronically infected HIV+ individuals148. Of the 81 viruses shown here, a subset of 16 viruses were chosen for 
analysis in pseudovirus-based infectivity assays. Of these 16 viruses, red dots represent tier 3, blue dots 
represent tier 2 and green dots represent tier 1B viruses. Clones that did not consistently cluster with tier 1 or 
tier 3 were categorized as tier 2. This is indicated by the single blue dot (clone 569-F1_37_10) that lies within 





3.2 Variable loop characteristics associated with neutralisation resistance 
!
Longer loops and increased glycan density has been associated with resistance to 
neutralisation with the V1V2 loop being a major driver of this association68. We analysed the 
V1, V2, V4 and V5 loop characteristics including length, glycan density and inferred net 
charge of 89 subtype C Envs in relation to their neutralisation phenotype. We found that the 
V2 loop net charge was negatively correlated with neutralisation resistance, and the V5 loop 
length was positively correlated with resistance in subtype C. In a similar analysis, with 8 
CRF02_AG viruses, the V2 loop length was positively correlated with resistance (Fig 3.2). 
We observed no correlation between V1V2 loop length and glycan density and neutralisation 
in the subtype C panel as other studies have reported68,148. This subset of 81 subtype C 
viruses was selected from a bigger panel of 200 viruses in which V1V2 loop length and 
glycan density was associated with resistance148. Thus, the lack of an observed association in 
this subtype C data set is plausibly due to our smaller sample size, and thus smaller statistical 






Figure 3.2. Variable loop characteristics of envs that correlate with neutralisation resistance. (a) V5 loop 
length is negatively correlated with neutralisation in subtype C but (b) is not significantly correlated in 
CRF02_AG. (c)V2 net charge is positively correlated with neutralisation in subtype C viruses but (d) is not 
significantly correlated in CRF02_AG. (e) V2 loop length is not associated with neutralisation in subtype C but 
is (f) negatively correlated with neutralisation in CRF02_AG. Loop length is measured in number of amino 
acids. 81 subtype C and 9 CRF02_AG sequences were used in the analysis. Sequences were downloaded from 
the LANL website and the variable region characteristics tool (on LANL) was used to calculate loop lengths and 
net charge. A Pearson’s or Spearman rank correlation was applied to all data sets depending on the distribution 
of data and graphs generated by Graphpad Prism (p<0.05). Significant p values are shown in red text. 
 
 
3.3 Relationship between neutralisation resistance and entry efficiency 
!
Neutralisation escape leads to selection of changes in Env that confer resistance to nAbs42. As 
Env mediates viral entry into target cells, these changes might impact entry efficiency. We 
therefore hypothesized that highly resistant viruses (tier 3) have incurred fitness costs as 
measured by entry efficiency. To test this, we used the tier designation143 (Fig 3.1) as a 
categorical designation of neutralisation resistance, and evaluated the selected panel of 16 
subtype C viruses designated as tier 3 (highly resistant), 2 and 1B (highly sensitive) for Env 
function by measuring entry efficiency and sensitivity to entry inhibitors. The panel was 
restricted to 16 viruses as the entry efficiency assays could not be performed on all 89 Envs.  
(Both entry and reverse transcriptase activity must both be measured, and each value shown 
is the geometric mean of measurements from two separate preparations of PSVs.) A 
description of the subtype C (Table 2.1) and CRF02_AG viruses (Table 2.2) is shown in 
chapter 2.  
Entry efficiency was calculated as the relative light units (RLU) generated in a PSV 
infectivity test per picogram of reverse transcriptase activity present in each viral stock 
(RLU/pg RT).  We first investigated whether neutralisation resistance correlated with entry 
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efficiency and found no overall correlation between neutralisation resistance and entry 
efficiency in either subtypes (Fig 3.4).  However, importantly, when we categorized the 
subtype C panel viruses into tiers, subtype C tier 3 viruses were significantly (p=0.014) more 
infectious that tier 2 viruses (Fig 3.3). Interestingly, these results were contrary to our original 
hypothesis; indicating that in these viruses, resistance did not result in decreased fitness as 
measured by entry efficiency. Within the tier 1B and tier 3 there were outliers with the 
highest entry efficiency; CAP174.1.06_F3_1B in the tier 1B and Ko243_H6.3 in the tier 3. 
With only three viruses in the Tier 1B group, it was not possible to make comparisons with 
other subtype C groups. This tiered comparison was not performed for the CRF02_AG 
viruses as they were too few to reliably tier categorize them by within-subtype neutralisation. 
For this reason, only the association with geometric mean ID50 is shown. 251-18 (105,423 
RLU/pg RT) was the most infectious of the CRF02_AG viruses. The most neutralisation 
sensitive subtype C and CRF02_AG viruses tested (CA146_H3_3 and 255_34 respectively) 
were also the least infectious isolates tested. Nonetheless, contrary to our hypothesis, there 
seems to be no cost to entry efficiency associated with resistance. 
 
                          !                      
 
Figure 3.3 Entry efficiency is increased in subtype C tier 3 viruses. Entry efficiency of env-typed PSVs was 
assessed using a single cycle entry assay on TZM-bl cells. The figure shows the entry efficiency expressed as 
RLU per pg of RT in infection experiments with each PSV. Red dots represent tier 3, blue squares represent tier 
2 and green triangles represent tier 1B viruses. Each symbol on the graph represents one PSV. The bars 
represent the median and interquartile range for all data sets. P-values were calculated by performing a Mann 
Whitney test and the graphs were generated using GraphPad Prism 
 



















Figure 3.4 Neutralisation sensitivity does not correlate with entry efficiency. Entry efficiency for all PSVs is 
plotted on the y-axis while the neutralisation sensitivity is plotted on the x -axis. (a) Represents subtype C PSVs 
coloured according to tiers (red dots=tier 3, blue squares=tier 2 and green triangles=tier 1B viruses) while (b) 
represents CRF02_AG PSVs. A Pearson’s rank correlation was applied to all data sets and graphs generated by 
Graphpad Prism. 
 
3.4 Neutralisation resistance and susceptibility to entry inhibitors 
!
Entry inhibition assays are a useful tool for uncovering functional differences between 
viruses in relation to one another. Hence, we investigated the effect of three inhibitors on 
virus entry. Inhibition sensitivities of the PSVs were determined using the 50% effective 
inhibitory concentration, that is, the concentration at which viral infectivity, measured as 
RLU, was inhibited by 50% in the presence of the drug (EC50). Maraviroc (MRV) blocks 
entry by binding CCR5 in a non-competitive manner178 while PSC RANTES competes with 
the virus for CCR5 binding and is an approximate test for CCR5 affinity179. Additionally, 
sensitivity to the fusion inhibitor T20 was measured.  
All viruses tested were R5-tropic viruses. Tier 3 viruses exhibited a wide range of EC50 
values for the various inhibitors (fig. 3.5). Overall, there was no significant association 
between neutralisation sensitivity and entry inhibition (Fig 3.5). A trend towards reduced 
sensitivity to Maraviroc in subtype C tier 3 viruses compared to tier 2 was observed (p=0.08) 
suggesting increased binding capacity to CCR5 of these viruses. We observed that the 
subtype C viruses that had reduced sensitivity to Maraviroc also had reduced sensitivity to 
T20. This is expected as T-20 can only inhibit fusion after CD4 attachment and before co-
receptor binding180. Two subtype C viruses; CAP260.2.00_TA1_1B and 
CAP291.2.00_H2.15 were the least sensitive to Maraviroc (8.9 and 8.8nM respectively) 
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suggesting that these viruses can still infect cells despite blocking of CCR5 by Maraviroc. 
Ko243_H6.3 was the least susceptible to PSC Rantes within the subtype C clones indicating 
that it has a high affinity to CCR5 and this could partially explain its high entry efficiency 
(Fig 3.6).  
 
 
Figure 3.5 Inhibition sensitivities of viruses do not correlate with neutralisation phenotype. Inhibition 
sensitivities represented as effective inhibitory concentrations (EC50) are represented on the y-axis for subtype C 
and CRF02_AG. (a,c,e) represents sensitivity of subtype C viruses to the inhibitors Maraviroc, PSC Rantes and 
T20 respectively. (b,d,f) represents sensitivity of CRF02_AG viruses to the inhibitors Maraviroc, PSC Rantes 
and T20 respectively. .Each point on the graph represents a PSV. The bars represent the median and 
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interquartile range for each group. The differences were not significant for any of the inhibitors, as indicated by 
the parentheses around the p values. 
 
3.5 Susceptibility to entry inhibitors and entry efficiency 
!
Next, we investigated which entry step correlated best with overall entry efficiency (Fig 3.7). 
We found that decreased susceptibility to PSC RANTES was associated with increased entry 
efficiency in CRF02_AG (r=0.9292, p=0.0008). However, this relationship is likely 
infulenced by the single point (100,000 RLU/pg/0.5 nM). This suggests that the relationship 
we are presenting could hinge entirely upon small errors in one data point.  This might not 
have been true if we had a larger set of CRF02_AG viruses to analyse in this manner.  
Decreased susceptibility to PSC RANTES indicates that the virus out-competes the inhibitor 
for binding to CCR5. Therefore, this result is expected as increased affinity to CCR5 would, 
theoretically, make the virus more likely to infect a target cell (if all other conditions were 
equivalent). We observed no correlation between entry inhibitors and subtype C entry 








Figure 3.6 Correlation between entry efficiency and entry inhibitors. Inhibition sensitivities represented as 
effective inhibitory concentrations (EC50) of the different inhibitors are represented on the x-axis, and entry 
efficiency on the y-axis. (a,c,e) represents subtype C viruses while (b,d,f) represents CRF02_AG viruses. A 
Pearson’s rank correlation was applied to all data sets and graphs generated by Graphpad Prism.  
 
 
3.6 V2 loop characteristics are associated with entry efficiency 
!
The variable loops play an important role in viral entry181. We further investigated which 
variable loop characteristics were associated with entry efficiency for the viruses that we 
assayed. Of all the loop characteristics tested (V1-V5 loop length, PNGs density and net 
charge), we found that, in subtype C viruses, increased glycosylation in the V2 loop was 
positively correlated with entry efficiency but not in CRF02_AG. On the other hand, the 
overall V2 net charge was negatively correlated with entry efficiency in CRF02_AG viruses 
but not in subtype C (Fig. 3.7). The differences in association between the two subtypes 
observed here may be explained by the lack of statistical power as both subtypes show a 
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trend in the same direction. Of note, this data highlights the importance of the V2 loop in 
mediating viral entry, and that the attributes of the V2 loop that we detected as important are 
different for subtype C and subtype CRF02_AG viruses. 
 
 
Figure 3.7 Entry efficiency correlates with V2 loop glycans and net charge. Entry efficiency for all PSVs is 
plotted on the y-axis while the neutralisation sensitivity is plotted on the x -axis. (a) Number of V2 loop glycans 
correlated with entry efficiency only in the subtype C viruses (b) but not in CRF02_AG; (c) V2 net charge did 
not correlate with entry efficiency in subtype C but (d) was negatively correlated in CRF02_AG viruses. A 
Pearson’s rank correlation was applied to all data sets with significant p-values indicated in red. Graphs were 
generated using Graphpad Prism. Note that the y-axis scale is different for the subtype C vs the subtype 
CRF02_AG viruses. CRF02_AG virus 251-18 is the only virus tested with entry efficiency over 60,000 RLU/pg 
RT. 
 
3.7 Differences in Env phenotypes between subtype C and CRF02_AG 
!
Genetic variation between subtypes in the env gene is often 25 to 35%182. Differential 
characteristics of viral subtypes and their interactions with the human host may influence 
HIV transmission and disease progression. For example, a prior study showed that there were 
more maraviroc and vicriviroc-resistance mutations naturally occuring in subtype C viruses 
compared to subtype B strains183. Additionally, more T20 resistance mutations were present 
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in non-subtype B strains than in subtype B184.  This might affect treatment with entry 
inhibitors.  We investigated the differences in Env phenotype between subtype C and 
CRF02_AG viruses. We found no significant differences between the subtypes in entry 
efficiency and susceptibility to Maraviroc, PSC RANTES and T-20 (Fig 3.8). However, we 
did observe a trend of increased susceptibility to PSC RANTES in the CRF02_AG viruses 
compared to subtype C suggesting that these CRF02_AG viruses had lower affinity for CCR5 
compared to the subtype C viruses. This might at least partially explain the difference in 
prevalence between these two subtypes. Maraviroc and T20 EC50 ranges were similar 
between the two subtypes. 251_18, a moderately to severely neutralisation resistant 
CRF02_AG virus, had the highest entry efficiency (105,423 RLU/pg RT) of all viruses 
tested, the only virus we tested with an entry efficiency over 60,000 RLU/pg RT.  
 
Figure 3.8 Phenotypic properties of subtype C and CRF02_AG do not significantly differ. Dot plots of (a) 
entry efficiencies (geometric mean RLU/pg RT) and sensitivity to (b) Maraviroc, (c) PSC Rantes and (d) T20 of 
both subtypes are shown. Each dot on the graph represents a PSV. The bars represent the median and 
interquartile range for each group. The differences were not significant for any of the inhibitors (p=0.05, 





3.8 Glycan conservation analysis and neutralisation sensitivity 
3.8.1 Univariate analysis 
Glycans on Env play an important structural role and mediate evasion from nAbs185. An 
analysis of HIV-1 escape mutants showed that most of the mutations acquired during 
antibody escape involved changes at the N-linked glycosylation sites42. We investigated the 
inferred glycan profile of Env based on neutralisation phenotype to determine if there were 
differences in the glycosylation patterns between the tiers. We analyzed the 200 subtype C 
sequences that had been categorized as tier 3, 2 or 1 previously143 based on within subtype 
neutralisation. This included 28 tier 3, 156 tier 2 and 16 tier 1B sequences. We included only 
subtype C in order to limit any confounding inter-subtype differences. This analysis was not 
done on CRF02_AG because of the small sample size (n=8). We used the N-glycosite tool on 
the LANL website which tallies all predicted N-glycan sites on the sequences. Sites that were 
conserved in 20-90% of the sequences were selected (Fig 3.9). 
 
Figure 3.9 Comparing PNGS conservation in viral sequences in the different tiers. The x axis 
represents the position of PNGs while the y-axis represents the proportion of a particular PNGs in the 
total sequence per tier (fraction). Black arrows indicate the glycan positions at which a difference in 
prevalence was observed between tiers. We used the N-glycosite tool on the LANL website to tally 
PNGS that are conserved in tier 3 (n=28), 2 (n=156) or 1B (n=16) and compared the three groups.  
 
N465 was more common in tier 3 (32%) and 2 (15%) viruses compared to tier 1B (6%) while 
N332 was enriched in tier 1B sequences (100%; 16/16) compared to tier 2 and 3 (68% and 




































































334 while some sequences lacked both N332 and N334 (6 tier 3 sequences and 29 tier 2 
sequences).  In addition, Tier 3 viruses were more enrinched with N355 (70%) compared to 
tier 2 and 1B and N139 was relatively more common (about 25%) compared to tier 3 (less 
than 10%).  
 
3.8.2 Bayesian model averaging analysis 
!
As some glycans can compensate for other glycans, this initial univariate analysis was not 
sufficient in informing us about which PNGs are strong predictors of resistance. Therefore, 
we used linear regression to fit the relationship between neutralisation sensitivity (geometric 
mean ID50, data for which was available for 87 viruses of the original 200) and presence or 
absence of each of the PNGs selected above (Fig 3.9). 22 PNGs were identified from the 
initial analysis as being present in 20-90% of the sequences across tier 1B, 2 and 3 (Fig 3.9). 
Glycan 334 was added back because of its strong negative association with N332 (mutually 
exclusive due to motif overlap) and N674 was removed because glycosylation at 674 in the 
Membrane Proximal external Region would interfere with fusion. Model selection using the 
Akaike information criterion (AIC) favoured models that included N137, N332, N386, N413 
and N446 as predictors, with the strongest likelihood of direct association with N413 and 
N332 (Table 3.1). To account for model selection uncertainty, we used Bayesian average 
modeling to combine all the models the AIC chose into a final model that could accurately 
predict neutralisation resistance. We report the posterior effect probability of this model for 
all 23 PNGs. The higher the probability (between 0-100%), the more evidence there is that 
the PNG has a direct effect on neutralisation, independent of the other glycans in the model. 
Based on this analysis, N413 and N332 were found to most likely influence neutralisation in 
these subtype C viruses independent of the presence or absence of PNGs at other sites. (Table 
3.1). N355 which was also picked up by the univariate analysis, was the fourth most 
important PNG for neutralisation. Interestingly, N413 was not picked up by the univariate 
analysis. This maybe because of the influence of N411 or other PNGs which are accounted 































 1 PNGs numbering is based on the reference sequence HXB2 
 2 The posterior effect probability indicates the calculated probability that the coefficient in the regression model 
used is not zero with model uncertainty taken into account. 
 
The presence of N413 and the lack of N332 was associated with neutralisation resistance (Fig 
3.10). This finding is consistent with previous reports143,186 and once again highlights the 





Figure 3.10 N332 and N413 are associated with neutralisation resistance in subtype C. The figure compares 
the neutralisation profile of 81 subtype C viruses that have or lack N332 and N413. (a) Absence of N332 was 
associated with neutralisation resistance while (b) Presence of N413 rendered viruses more resistant to 
neutralisation. The log geometric mean ID50 is plotted on the y axis and represents neutralisation sensitivity. 
Each symbol on the graph represents one virus. The bars represent the median and interquartile range for all 
data sets. P-values were calculated by performing a Mann whitney test and the graphs were generated using 
GraphPad Prism.                
 
3.9 Tier 3 viruses are resistant to the commonly tested broadly neutralising 
antibodies 
!
We wished to better understand which epitopes of Env are important for overall 
neutralisation resistance. As the commonly studied bnAbs have well defined epitopes; 
increased resistance to a particular bnAb in highly resistant viruses would indicate which 
epitopes play a role in driving resistance during escape. Therefore, we investigated if tier 3 
viruses have differing sensitivity to the commonly studied bnAbs compared to tier 2 and 1B 
viruses. This analysis included only bnAbs with data for all tier 3 viruses were considered. 
Using the CATNAP tool on the LANL website, we compared IC50 values of 200 subtype C 
viruses categorized as tier 3, 2 or 1 previously143 by within subtype neutralisation and had 
been tested against a number of bnAbs.  
 
We found that tier 3 viruses were significantly more resistant to PGT121, 4E10 and the 
CD4bs antibodies (3BNC117 and VRC01) but not the V1/V2 bnAbs (PG9 and PGT145) 
compared to tier 2 and 1 (Fig 3.11).  There were differences in sensitivity between tier 1 and 
tier 3 in 10-1074, PGT128 and 10E8, however, there were no differences between tier 2 and 
tier 3 viruses to these bnAbs.  Together, this data suggests that the antibody selection pressure 






Figure 3.11 Tier 3 viruses are more resistant to bnAbs. Dot plots show the distribution of antibody titres 
represented by IC50 towards tier 3 (n=28), 2 (n=149) and 1 (16) viruses. The horizontal line and error bars  
indicates the mean and standard error of mean for each group. (a) V3 glycan antibodies 10-1074, PGT121 and 
PGT128. (b) MPER antibodies 4E10 and 10E8 (c) V1/V2 antibodies PG9  and PGT145 (d) CD4bs antibodies: 
VRC01  and 3BNC117. Tier 3 viruses were more resistant to the V3 glycan antibodies (10-1074, PGT121 and 
PGT128), the MPER antibodies 4E10 and 10E8 and the CD4bs antibodies VRC01 and 3BNC117. bnAb data 
was available on the LANL website. Each symbol on the graph represents one virus. Significant differences 
between medians are indicated by P-values for the Kruskal-Wallis test with multiple comparisons.   * p≤0.05,











Induction of broad and potent neutralising antibodies (nAbs) by a vaccine remains a major 
goal of HIV-1 vaccine research50. In addition, broadly neutralising antibodies (bnAbs) offer 
an avenue for novel therapeutics and are considered a blueprint for vaccine immunogen 
design. In natural infection, HIV-1 co-evolves with the neutralising antibody response 
leading to viral escape and resistance187–190. In fact, several studies suggest that HIV-1 is 
evolving towards increased resistance to antibody neutralisation at a population level10,11,143. 
Transmission of neutralisation resistant viral variants would have significant implications for 
antibody-based interventions including vaccines and bnAb therapy. This study investigated 
the characteristics of a subset of highly neutralisation resistant viruses classified as ‘tier 3’. 
Our aim was to characterise and identify genetic and functional differences between Envs of 
resistant viruses and sensitive viruses. 
4.1 Genetic features associated with resistance 
!
Several studies have shown that genetic characteristics of Env including increased length and 
number of PNGs in the V1V2 loop region are a feature of neutralisation resistant viruses142. 
Long loops and increased glycan density are thought to mediate resistance by occluding 
antibody epitopes. We assessed variable loop characteristics (length, number of glycans and 
net charge) in 81 subtype C viruses with differing neutralisation resistance profiles and found 
that only V2 net charge and V5 loop length were inversely associated with neutralisation 
resistance, however not V1V2 loop length nor the number of PNGs in V1V2 loop region (Fig 
3.2). This finding in the subtype C panel was inconsistent with previous studies that reported 
associations between resistance and the V1V2 loop length and glycan density68,148. A small 
sample size may explain the lack of consensus. The 81 viruses analysed here were part of a 
larger panel of 200 subtype C viruses. Analysis of the 200 viruses showed an association 
between V1V2 loop length and neutralisation resistance148. The need for a large sample size 
to detect these associations indicates that the V1V2 length and glycan density may not be a 
strong predictor of neutralisation resistance in subtype C.  Furthermore, neutralisation 
resistance can also be mediated by the structure of the V1V2 loop which may not be easily 
visible by analysing primary amino acid sequence variation191. Thus, while loop 
characteristics are associated with neutralisation resistance, many other factors mediate 
resistance and the important loop characteristics are not always easily discerned by analysis 
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of the amino acid sequence alone.  Interestingly, in our panel of only eight CRF02_AG 
viruses, we found that only the V2 loop length was detectably negatively correlated with 
neutralisation resistance as found in previous reports (Fig 3.2). This also highlights potential 
inherent differences between subtypes for these properties. 
4.2 Neutralisation resistance and Env function 
!
Env mediated viral entry has been reported to have the greatest influence on replication 
fitness164,192. Reports from a number of studies suggest that the difference in neutralisation 
phenotypes could be explained by differences in Env structure86,193,194.  Cai et al. (2017) 
report that Envs of resistant viruses exhibit a very narrow range of pre-fusion conformations 
with most epitopes occluded86. It is plausible that these changes to structure affect viral entry 
as such changes to Env that block antibody binding may also block key Env-target cell 
interactions during entry85. Therefore, a better understanding of the interplay between overall 
neutralisation resistance and viral fitness is important. In the present study, we evaluated the 
association between antibody resistance and viral entry efficiency (as a component of viral 
fitness). We expected to observe decreased entry capacity in highly resistant viruses. We 
hypothesized that this may explain why the most highly resistant isolates are generally 
underrepresented compared to moderately resistant isolates (tier 2), and that prolonged 
chronic infection under intense antibody pressure does not often result in selection of a tier 3 
virus. However, in the subset of subtype C viruses we tested, tier 3 viruses had significantly 
higher entry efficiency compared to tier 2 (Fig 3.3), the opposite direction of what we had 
hypothesized. This finding is also not easily consistent with results from an HIV-1 infected 
individual who was treated with B cell ablative therapy for a malignancy. During the period 
of treatment in which this individual’s antibody responses were suppressed, a neutralisation 
sensitive variant emerged and the viral load was higher, suggesting increased viral fitness 
compared to the neutralisation-resistant variant that dominated in the presence of antibody122. 
We propose two possible explanations for our observation. First, it is likely that the epitope 
specificities of the dominant nAb response in the serum panels used to define resistance may 
determine whether resistance will result in a fitness cost. In an instance where nAbs target 
regions of Env that are critical for function, then it is likely that escape will impart a fitness 
cost. For example, escape from an N332 response by shifting the glycan to position 334 had 
no significant impact on entry efficiency in CAP177 virus 195. On the other hand, viruses that 
escape PG9/PG16 and VRC01 have been shown to have reduced entry efficiency196. This 
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may be evident in CA146, which lacks a glycan at position 160 making it resistant to PG9, 
and is also the least infectious subtype C virus in our subset. Overall, it is likely the tier 3 
viruses tested here acquired changes on regions of Env (such as the V3 glycan patch) without 
affecting entry efficiency.  
Second, selection of circulating viral variants is the result of an optimal balance between 
immune escape and fitness. Viruses with mutations that confer escape without a fitness cost 
will likely become dominant and maintained in the population. On the other hand, viruses 
with decreased fitness may be harder to detect as they are fewer in circulation. Thus it may be 
necessary to isolate more Env clones and substantially increase the sample size in order to 
detect viruses with decreased fitness.  
Altogether, our results suggest that reduced entry efficiency is not the primary explanation 
for the apparent under representation of tier 3 viruses, even after years of chronic infection 
and antibody-mediated selection of HIV-1 populations. We were not able to shed light on 
why such viruses seem to appear less frequently among HIV-1 isolates taken from chronic 
infection (i.e. after substantial selection by antibody). 
4.3 Susceptibility to entry inhibitors 
!
The resistance pathway against nAbs may involves changes to the Env protein which is also a 
target for entry inhibitors. For this reason we investigated if there was any relationship 
between neutralisation resistance and susceptibility to entry inhibitors. Some studies have 
reported that greater sensitivity to neutralisation was associated with resistance to CCR5 and 
fusion inhibitors197,198. However, we observed no significant association between 
neutralisation resistance and susceptibility to entry inhibitors (Fig 3.5). The likely explanation 
for this discrepancy is that what is measured here are variations in resistance to Maraviroc 
and T20 occurring naturally in viruses. On the other hand, the studies that show an 
association between neutralisation and susceptibility to inhibitors used viruses that had been 
selected by their resistance to the inhibitors. These viruses contained known mutations on 
Env that also affected neutralisation197,198.  
Further, we defined the mechanisms involved in differential entry efficiency by using entry 
inhibitors that target different points of the entry process. Reduced viral fitness has been 
associated with increased susceptibility to CCR5 inhibitors and fusion inhibitors199 
presumably because the increased susceptibility to CCR5 inhibitors signals decreased CCR5 
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affinity/binding which in turn probably reduced entry efficiency. In the CRF02_AG viruses 
tested here, decreased susceptibility to PSC RANTES correlated with increased entry 
efficiency (Fig 3.6). This was not surprising as higher affinity to CCR5 (as measured by 
reduced inhibition with PSC RANTES) would presumably be a significant factor in 
influencing entry efficiency.  
4.4 Glycan sites associated with resistance 
!
Up to 50% of Env is covered in glycans and can block access of nAbs to neutralisation 
epitopes42,44,113,185,200–202. Wei et al. (2003) analysed escape mutants that arose in response to 
the autologous nAb response. They reported that changes in potential N-glycosylation sites 
(PNGS) were the most common mutations in these viruses42. Some glycans are evolutionarily 
conserved in HIV-1 sequences; however, the absence or presence of many glycans varies in 
different viruses. On average, Env matures from a less glycosylated state to the more fully 
glycosylated Env as the virus evolves in an individual203 as transmitted/acute viruses have 
been shown to be less glycosylated relative to chronic viruses. We considered the role 
glycans play in overall neutralisation resistance in subtype C viruses and hypothesized that 
the resistant viruses would have a different glycosylation pattern compared to more sensitive 
viruses. The glycan at position 465 was enriched in tier 2 and 3 viruses compared to tier 1B 
(Fig 3.9); however, it did not show up as a likely independent correlate in the Bayesian model 
averaging analysis (Table 3.1), suggesting that it may not have been independently associated 
with neutralisation resistance. Similarly, The independent contribution of N355 to the best fit 
Bayesian averaged model is less than 1/6 that of N413 and about 1/3 that of N332. The 
glycans at position 413 (V4) and 332 (V3 base) were independently associated with 
neutralisation. Similar to previous reports, a glycan at position 413 was associated with 
decreased sensitivity to neutralisation in subtype B viruses186. N413 is also proximal to some 
CD4bs mAb epitopes and is associated with resistance to b12 (a CD4bs mAb)186. The glycan 
at position 332 is described as a supersite of vulnerability and for antibody recognition by the 
PGT and PGT-like bnAbs44,109,110. A shift from N332 to N334 has been shown to result in 
escape from strain specific responses44,195. The association of the absence of N332 with 
neutralisation resistance showed up more strongly than N334 in the bayesian association 
analysis, although it is difficult to rule out that this was due to a reduced statistical power 





4.5 Resistance to commonly tested broadly neutralising antibodies 
!
We evaluated if there were differences in neutralisation sensitivity to bnAbs between 
sensitive and highly resistant viruses to investigate the epitopes that may drive resistance. 
The most consistent differences were evident in the V3/glycan bnAbs PGT121 (Fig 3.11). A 
number of studies have shown the effect of changes in N332/4 on neutralisation by 
V3/glycan mAbs44,109,200. Rademeyer et al. (2016) proposed that the resistance phenotype of 
tier 3 viruses in their clade C subset could be partially explained by lack of the N332 
glycan143. However, PGT121 can neutralise both N332 and N334 viruses109 and also uses the 
glycans at position 137,156 and 301109 and so may not depend on 332 as much as 10-1074 
does. Treatment of chronically HIV-1 infected individuals with 10-1074 resulted in escape 
mutants that had eliminated the glycan at position 332 making them resistant to 10-1074112. 
We also observed differences in sensitivity between tier 2 and tier 3 subtype C viruses to the 
CD4bs antibodies VRC01 and 3BNC117 and the MPER antibodies 4E10 (Fig 3.11). 
Interestingly, there were no detected changes in neutralisation sensitivity between tier 3, 2 
and 1 viruses against PG9 and PGT145. One possible explanation for the differential 
sensitivity to these bnAbs observed here is that antibodies against the V3/glycan site, CD4bs 
and MPER are elicited in a substantial proportion of HIV-1+ individuals and viruses resistant 
to these antibodies are selected for in the population.  Antibody based selection resulting 
from on going viral escape has been well documented42,204,205.  
Similarly, several studies have shown that contemporary HIV-1 isolates are more resistant to 
a number of bnAbs including those shown here compared to viruses isolated early in the 
epidemic10,12,145. Collectively, these data also suggest that resistance testing of viruses to 
bnAbs might be inevitable before introducing bnAbs as therapies. 
4.6 Phenotypic differences between subtypes 
!
The HIV-1 env gene can vary between subtypes by 35% of the amino acids with the gp120 
bearing most of this diversity206. Such diversity can result in differences of Env function. 
Recent studies have revealed differences between subtypes in in vitro replication fitness207,208 
and rate of disease progression209,210. The relative replicative fitness of a virus likely 
influences the prevalence of viral subtypes pointing to the importance of within subtype 
comparisons. CRF02_AG is dominant in West and West Central Africa while subtype C 
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viruses are responsible for the vast majority of HIV-1 infections in southern Africa and India, 
and is responsible for half of all global infections211.  Differences in replicative fitness have 
been shown between subtype C and B164. In our study, we found no significant phenotypic 
differences between subtype C and CRF02_AG as measured by entry efficiency and 
susceptibility to entry inhibitors (Fig 3.8). However, a growth competition assay could 
possibly yield more conclusive results as it is a more sensitive test of replication212. 
A higher number of glycans in the V2 region was associated with increased entry efficiency 
in subtype C while a high V2 net charge negatively associated with entry efficiency in 
CRF02_AG.  These differences are not surprising as the loop regions are highly variable even 
within subtypes in addition to the inherent inter-subtype differences. There is evidence to 
suggest that adaptive pressures that shape Envs of different subtypes are distinct213. This 
could lead to subtle but significant sequence and structural differences between the subtypes 








Overall, we report increased entry efficiency in a subset of subtype C tier 3 viruses compared 
to tier 2 viruses. Therefore, we conclude that decreased entry efficiency could not explain the 
low frequency of tier 3 viruses in chronic HIV-1 infection. Chronic HIV-1 infection is the 
stage in which antibody would presumably be capable of selecting for such highly 
neutralisation-resistant variants. Some studies do show that changes in Env associated with 
escape from neutralising antibody leads in a loss of Env fitness214,215. However, the 
association between entry efficiency and neutralisation resistance that we detected was in the 
opposite direction.  
We also report the importance of two PNGs in neutralisation resistance in subtype C 
consistent with previous data. Presence of a glycan at position 413 is associated with 
resistance while lack of a glycan at position 332 was associated with resistance to 
neutralisation.  Additionally, tier 3 viruses are significantly more resistant to neutralisation by 
the V3 glycan (PGT121), CD4bs (VRC01 and 3BNC117) and MPER (4E10) bnAbs. This 
may result from the fact that nAbs against these epitopes are elicited in a significant 
proportion of the population and contribute substantially to selection of the resistant variants 
in the population. As bnAbs are being explored for treatment, circulating resistant viruses 
would reduce the efficacy of these bnAbs. Furthermore, consistent with previous reports, we 
confirm that the V2 region (in our case, glycan density and net charge) is associated with 
entry efficiency216,217. Finally, our findings provide more evidence that for antibody based 
interventions to be globally relevant, they must target regions of the virus that are more prone 
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